US FDA chief looks back on 2008

12 January 2009

In his weekly "My Take" blog on the US Food and Drug Administration's web site, Andrew von Eschenbach, who will soon be relinquishing his post  as Commissioner in the incoming Barack Obama administration, gave his  annual self-appraisal of what had been achieved during the past year,  which he says is a useful exercise for government entities such as the  FDA.

He said: "when I arrived at FDA more than three years ago, I set five  priorities or resolutions. They were to prepare the agency for strong  performance in the case of a public health emergency; improve the FDA's  internal and external communications; maximize the use of electronic  data and insights provided by projects in personalized medicine, like  the Human Genome Project; continue the implementation of modern  scientific tools for regulation in medical products through our agencies  our agency's Critical Path Initiative; and advance the FDA's outreach  globally to ensure that imported food and drugs measure up to the United  States' standards."

In his January 2 message, he claims that "the progress that we've made  toward all of these goals now serves as a New Year's resolution to do  even more."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight